Aerie Pharmaceuticals to Participate in Two Investor Conferences in June
Aerie Pharmaceuticals, Inc. (Nasdaq:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye, announced today that Vicente Anido, Jr., Ph.D., Chief Executive Officer and Chairman of the Board, will present an overview of the company at the following conferences in June.
- Jefferies 2015 Healthcare Conference
- Presentation Date: Wednesday, June 3, 2015
- Presentation Time: 2:30pm E.T.
- JMP Securities Life Sciences Conference 2015
- Presentation Date: Tuesday, June 23, 2015
- Presentation Time: 11:00am E.T.
The presentations will be webcast live and may be accessed by visiting Aerie’s website at http://investors.aeriepharma.com/. A replay of each webcast will be available for 10 business days.
About Aerie Pharmaceuticals
Aerie is a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye. The Company is conducting a Phase 3 registration trial in the United States, named “Rocket 2,” where the primary efficacy endpoint will be to demonstrate non-inferiority of IOP lowering for RhopressaTM compared to timolol, along with a Phase 3 registration safety-only trial, named “Rocket 3,” in Canada. The Company recently completed its initial Phase 3 registration trial, “Rocket 1,” the three-month efficacy results of which were initially reported on April 23, 2015. The Company also completed in 2014 a Phase 2b clinical trial for RoclatanTM.
Sorry. No data so far.